Rejection

(redirected from Immune rejection)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.
Related to Immune rejection: Organ rejection

Rejection

Refusal by a bank to grant credit, usually because of the applicants financial history, or refusal to accept a security presented to complete a trade, usually because of a lack of proper endorsements or violation of rules of a firm.

Rejection

1. A bank's refusal to grant a line of credit. This often applies to the refusal to grant a mortgage loan to an uncreditworthy person or a business loan to someone without a proper business plan.

2. An investor's refusal to accept a security presented to him/her/it. Reasons for this include suspicion of fraud or improperly filled-out forms.

3. Refusal to provide insurance coverage because the insurance company believes that the claim describes a service or situation that the policy does not cover.

rejection

The refusal to accept a security that has been delivered by a customer or broker. A questionable certificate or an improper endorsement are reasons for rejection.
References in periodicals archive ?
That combination was CTLA4-lg, an FDA-approved drug for treating rheumatoid arthritis that suppresses T-cells responsible for immune rejection, and a protein called PD-L1 known to be important for inducing immune tolerance in tumors.
ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups.
Further, even if immune rejection occurs, it does not follow that cloning for autologous transplantation is the ideal solution to the problem.
And, while these cells may be useful in BMT-like therapies, an additional significant aspect of this work is the prospect of using these cells to prevent immune rejection when other hESC-derived cells are transplanted.
In other words, we can expect immune rejection to be a concomitant of successful differentiation, and an intrinsic limitation to treatments based on these sixty lines.
Implantation of human embryonic or autologous, ex vivo-expanded adult stem cells, particularly in older individuals, could circumvent the limited availability of organs/tissues as well as prevent complications related to immune rejection and disease transmission.
The capability of customized treatment, by utilizing patient's own blood cells, may have little serious adverse reactions such as immune rejection.
Denis-Claude Roy are leading clinical trials to reduce immune rejection of transplanted tissues.
They suggested that it might be possible to overcome the risk of immune rejection of the donor cells in humans.
Retinal transplantation is an invasive procedure that brings with it a variety of concerns such as immune rejection and the source of cells.
A drug originally devised to prevent immune rejection of organ transplants can lessen relapses in patients with multiple sclerosis, a new study finds.
As with more conventional types of transplants, immune rejection is a major potential problem.